Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
31 août 2022 17h30 HE
|
Interpace Biosciences, Inc.
Interpace Transitions to focused Molecular Diagnostics BusinessDisposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 ...
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
15 août 2022 16h05 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
16 mai 2022 16h15 HE
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE)...
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
11 mai 2022 08h30 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced that in...
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
31 mars 2022 16h15 HE
|
Interpace Biosciences, Inc.
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests
22 févr. 2022 09h00 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, announced today that the...
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
28 janv. 2022 19h35 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was...
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
27 janv. 2022 16h05 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay...
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
12 janv. 2022 16h41 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully...
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
03 janv. 2022 17h07 HE
|
Interpace Biosciences, Inc.
Proceeds to be used to fund the organic growth and prospective product line acquisitions PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”)...